SHR 2017
Alternative Names: SHR-2017Latest Information Update: 28 Aug 2025
At a glance
- Originator Suzhou Suncadia Biopharmaceuticals
- Class Immunotherapies; Monoclonal antibodies; Osteoporosis therapies
- Mechanism of Action Nerve growth factor modulators; RANK ligand modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Bone metastases
- Phase I Osteoporosis
Most Recent Events
- 28 Jul 2025 Adverse events and pharmacodynamics data from a phase Ib trial in Bone metastases presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)
- 24 Jun 2025 Phase-II clinical trials in Bone metastases in China (Parenteral) (NCT07028268)
- 19 Jun 2025 Suzhou Suncadia Biopharmaceuticals plans phase-II trial for Bone metastases in June 2025 (Injection) (NCT07028268)